Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study

Continuous intravenous epoprostenol improves exercise capacity, haemodynamics, and survival in severe primary pulmonary hypertension. Pulmonary hypertension can also be life-threatening in patients with connective tissue diseases. In a prospective open monocentre uncontrolled study, the effects of epoprostenol were evaluated in patients with severe pulmonary hypertension secondary to connective tissue diseases who were unresponsive to oral vasodilators (including calcium channel blockers) and continued to be in the New York Heart Association (NYHA) functional class III or IV despite conventional medical therapy. Seventeen patients received epoprostenol administered by a portable infusion pump associated with conventional therapy (oral anticoagulants, diuretics, supplemental oxygen). During the first six weeks of therapy, two (12%) patients died, of pulmonary oedema (n = 1) and severe sepsis (n = 1). In the fifteen remaining subjects, clinical and haemodynamic parameters improved significantly at six weeks. These patients were subsequently monitored for 80+/-48 (range 14-154) weeks after initiation of epoprostenol. Five (33%) patients died, of right heart failure (n = 2), severe sepsis (n = 2) or syncope (n = 1) and two patients were successfully transplanted 24 and 52 weeks after initiation of epoprostenol. Seven of the remaining eight patients had a persistent clinical improvement. Short-term epoprostenol therapy is effective in some patients with connective tissue diseases as demonstrated by better clinical status and haemodynamics at six weeks. However, this study reports several cases of early and late major complications including severe sepsis and pulmonary oedema. Additional information is needed to evaluate the benefit: risk ratio of long-term epoprostenol therapy in pulmonary hypertension secondary to connective tissue diseases.

This article has been cited by other articles:

				K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 691 - 699. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]

				M. Rubenfire, V. V. McLaughlin, R. P. Allen, G. Elliott, M. H. Park, M. Wade, and R. Schilz Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension: A Controlled Trial Chest, September 1, 2007; 132(3): 757 - 763. [Abstract] [Full Text] [PDF]

				A. C. Widlitz, S. McDevitt, G. R. Ward, and A. Krichman Practical Aspects of Continuous Intravenous Treprostinil Therapy Crit. Care Nurse, April 1, 2007; 27(2): 41 - 50. [Full Text] [PDF]

				C. M. Kahler and D. Colleselli Pulmonary arterial hypertension (PAH) in connective tissue diseases Rheumatology, October 1, 2006; 45(suppl_3): iii11 - iii13. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland, V. F. Tapson, R. L. Benza, V. V. McLaughlin, A. Krichman, A. C. Widlitz, and R. J. Barst Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1586 - 1589. [Abstract] [Full Text] [PDF]

				N Galie, A Manes, K V Farahani, F Pelino, M Palazzini, L Negro, S Romanazzi, and A Branzi Pulmonary arterial hypertension associated to connective tissue diseases Lupus, September 1, 2005; 14(9): 713 - 717. [Abstract] [PDF]

				Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]

				M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF]

				M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galie, A. Boonstra, L.J. Rubin, E.M. Horn, A. Manes, and G. Simonneau Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur. Respir. J., September 1, 2004; 24(3): 353 - 359. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J. Am. Coll. Cardiol., July 2, 2003; 42(1): 158 - 164. [Abstract] [Full Text] [PDF]

				K. P. Kuhn, D. W. Byrne, P. G. Arbogast, T. P. Doyle, J. E. Loyd, and I. M. Robbins Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 580 - 586. [Abstract] [Full Text] [PDF]

				S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky, and S. E. Kimmel Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis Chest, February 1, 2003; 123(2): 344 - 350. [Abstract] [Full Text] [PDF]

				R. J. Barst, S. Rich, A. Widlitz, E. M. Horn, V. McLaughlin, and J. McFarlin Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension* : Open-Label Pilot Study Chest, June 1, 2002; 121(6): 1860 - 1868. [Abstract] [Full Text] [PDF]

				J.-L. Vachiery, N. Hill, D. Zwicke, R. Barst, S. Blackburn, and R. Naeije Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension* Chest, May 1, 2002; 121(5): 1561 - 1565. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF]

				I. R. Preston, J. R. Klinger, J. Houtchens, D. Nelson, S. Mehta, and N. S. Hill Pulmonary Edema Caused by Inhaled Nitric Oxide Therapy in Two Patients With Pulmonary Hypertension Associated With the CREST Syndrome Chest, February 1, 2002; 121(2): 656 - 659. [Abstract] [Full Text] [PDF]

				V. CASTELAIN, D. CHEMLA, M. HUMBERT, O. SITBON, G. SIMONNEAU, Y. LECARPENTIER, and P. HERVE Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 338 - 340. [Abstract] [Full Text] [PDF]

				C D Vizza, S Sciomer, S Morelli, C Lavalle, P Di Marzio, D Padovani, R Badagliacca, A R Vestri, R Naeije, and F Fedele Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue Heart, December 1, 2001; 86(6): 661 - 665. [Abstract] [Full Text] [PDF]

				British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]

				T. Gessler, T. Schmehl, M.M. Hoeper, F. Rose, H.A. Ghofrani, H. Olschewski, F. Grimminger, and W. Seeger Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension Eur. Respir. J., January 1, 2001; 17(1): 14 - 19. [Abstract] [Full Text] [PDF]

				R. J. Barst Experience and Reason Chest, January 1, 2000; 117(1): 2 - 5. [Full Text] [PDF]

				A. Resten, S. Maitre, M. Humbert, O. Sitbon, F. Capron, G. Simoneau, and D. Musset Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure Radiology, March 1, 2002; 222(3): 782 - 788. [Abstract] [Full Text] [PDF]